OTCMKTS:CTTC - Calmare Therapeutics Stock Price, News & Analysis

$0.17
0.00 (0.00 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$0.17
Now: $0.17
$0.17
50-Day Range
$0.1010
MA: $0.12
$0.17
52-Week Range
$0.0111
Now: $0.17
$0.2374
VolumeN/A
Average Volume9,761 shs
Market Capitalization$5.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CTTC
CUSIPN/A
Phone203-368-6044

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 million

Profitability

Miscellaneous

Employees7
Market Cap$5.16 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CTTC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTTC and its competitors with MarketBeat's FREE daily newsletter.


Calmare Therapeutics (OTCMKTS:CTTC) Frequently Asked Questions

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

Has Calmare Therapeutics been receiving favorable news coverage?

Media headlines about CTTC stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Calmare Therapeutics earned a news impact score of 0.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Calmare Therapeutics.

Who are some of Calmare Therapeutics' key competitors?

What other stocks do shareholders of Calmare Therapeutics own?

Who are Calmare Therapeutics' key executives?

Calmare Therapeutics' management team includes the folowing people:
  • Mr. Conrad F. Mir, Pres, CEO & Director (Age 50)
  • Mr. Thomas Philip Richtarich M.B.A., Chief Financial Officer (Age 66)
  • Ms. Donna J. Mays, Mang. of Admin. Services
  • Dr. Stephen J. D'Amato, Chief Medical Officer & Member of Medical Advisory Board (Age 71)
  • Mr. William Lipford, Division Head of Product Sales

How do I buy shares of Calmare Therapeutics?

Shares of CTTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Calmare Therapeutics' stock price today?

One share of CTTC stock can currently be purchased for approximately $0.17.

How big of a company is Calmare Therapeutics?

Calmare Therapeutics has a market capitalization of $5.16 million and generates $1.11 million in revenue each year. Calmare Therapeutics employs 7 workers across the globe.View Additional Information About Calmare Therapeutics.

What is Calmare Therapeutics' official website?

The official website for Calmare Therapeutics is http://www.calmaretherapeutics.com/.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The company can be reached via phone at 203-368-6044 or via email at [email protected]


MarketBeat Community Rating for Calmare Therapeutics (OTCMKTS CTTC)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about Calmare Therapeutics and other stocks. Vote "Outperform" if you believe CTTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Featured Article: What is an economic bubble?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel